Board Meetings for MARKSANS
Detailed list of historic and upcoming board meetings.
| Symbol | Company | Meeting Date | Purpose | Description | Links |
|---|---|---|---|---|---|
| MARKSANS | Marksans Pharma Limited | 31 Jul 2006 | Unaudited Financial Results for the Qtr ended June 30, 2006 | - | - |
| MARKSANS | Marksans Pharma Limited | 29 Jun 2006 | Audited Results/Amalgamation/Issue of Securities/others | In addition to consideration of Audited results for the Financial Year ended March 31, 2006 the following business, will also be transacted (i) To consider and approve issue of securities in the form of ADR/GDR/FCCB's. (ii) To consider and approve Amalgamation of Mark Remedies Limited (Transferor Company) (100% subsidiary of Marksans Pharma Limited) with Marksans Pharma Limited (Transferee Company). (iii) Any other business with the permission of the Chair. (Purpose Revised). | - |
| MARKSANS | Marksans Pharma Limited | 29 Jun 2006 | Audited quarterly results | To take on record audited quarter results for the quarter ended March 31, 2006. | - |
| MARKSANS | Marksans Pharma Limited | 29 Jun 2006 | Audited Results | Marksans Pharma Limited had informed the Exchange regarding the Board Meeting to be held on June 29,2006 to take on record audited quarter results for the quarter ended March 31, 2006. The company has now informed the Exchange that the company has written the words "audited quarterly results for the quarter ended March 31,2006", instead of "Audited results for the Financial year ended March 31,2006". (purpose revised) | - |
| MARKSANS | Marksans Pharma Limited | 31 Jan 2006 | Unaudited Financial Results for the Qtr ended Dec 31, 2005 | - | - |
| MARKSANS | Marksans Pharma Limited | 29 Oct 2005 | Quarterly results | (1) To take on records quarterly results for the quarter ended September 30, 2005. (2) Any other business with the permission of the Chair. | - |
| MARKSANS | Marksans Pharma Limited | 18 Oct 2005 | Miscellaneous | To consider the following business :- 1) To make allotment of shares pursuant to amalgamation. 2) To consider amendment of the Object Clause of the Memorandum of Association of the Company. 3) Any other business with the permission of the Chair. | - |
| MARKSANS | Marksans Pharma Limited | 28 Jul 2005 | Unaudited Financial Results for the qtr ended June 30, 2005 | - | - |
| MARKSANS | Marksans Pharma Limited | 28 Apr 2005 | Unaudited Financial Results for the Qtr ended March 31, 2005 | Tasc Pharmaceuticals Limited has informed the Exchange that Meeting of the Audit Committee of the Company will be held on April 28, 2005, to take on record the un-audited financial results of the Company for the quarter ended March 31, 2005. | - |
| MARKSANS | Marksans Pharma Limited | 14 Apr 2005 | Miscellaneous | To consider, Inter alia, issue of Foreign Currency Convertible Bonds (FCCB) / Global Depository Receipts (GDR), for financing acquisitions in the US and Europe or elsewhere and to revamp its R&D operations and to bolster its research pipeline, to expand in its API business and enhancing its presence in Bio-pharmaceuticals business. | - |
| MARKSANS | Marksans Pharma Limited | 18 Mar 2005 | Miscellaneous | To consider and approve, Memorandum of Understanding entered with Glenmark Laboratories Limited for an alignment pact to create a research driven, fully vertically integrated and scalable globally competitive company having presence in the entire value chain of API, formulations and bio-pharmaceuticals. | - |
| MARKSANS | Marksans Pharma Limited | 18 Mar 2005 | Merger | TASC Pharmaceuticals Limited has informed the Exchange that they have entered into a memorandum of Understanding (MOU) for an amalgamation/merger of Glenmark Laboratories Ltd.. (GLL) with Tasc Pharmaceuticals Ltd.. (TPL), subject to approval of the Board of Directors of the respective companies and the H'ble High Court. The enterprise valuation of GLL has been done by Deloitte, Hafkins & Sells (DHS), of Rs.762 crores. On that basis, the MOU was entered into by the two parties proposing the likely ratio of merger of 1.8:1 i.e. the shareholders of GLL to get 1.8 shares of TPL for every 1 share held in GLL. The ratio has been arrived based on the fair business valuation of GLL and average market price of TPL during the last two weeks. The ratio is tentative and subject to approval of the Board of Directors of the respective companies. GLL had called for a press conference to announce the basic terms and nature of MOU for this alignment/amalgamation. (purpose revised). | - |
| MARKSANS | Marksans Pharma Limited | 24 Feb 2005 | Allotment of shares | To consider,inter alia,allotment of 15,00,000 shares(second conversion) to the holders of convertible share warrants. | - |
| MARKSANS | Marksans Pharma Limited | 27 Jan 2005 | Unaudited Financial Results for the Qtr ended Dec 31, 2004 | - | - |
| MARKSANS | Marksans Pharma Limited | 01 Dec 2004 | Allotment of shares | to consider,inter alia,allotment of 10,00,000 shares(first conversion) to the holders of convertible share warrants. | - |